Showing 61-70 of 332 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Program to Achieve FDA Agreement on Design of Confirmatory Trial for Verapamil | Kinexum LLC | Michael Zemel | Cures | 01-December-2024 to 30-June-2025 | $160,000.00 |
| T1D Adjunct Therapy Product & Patient Profiling Study | Magnolia Innovation, LLC | Kenneth Howie | Improving Lives | 01-December-2024 to 30-September-2025 | $434,000.00 |
| Combining Arteriovenous Bundle and ECM-Based Biomaterial Technologies to Induce Potent Neovascularization Following Islet Transplantation | Wake Forest University Health Sciences | Giuseppe Orlando | Cures | 01-April-2025 to 31-March-2026 | $248,692.00 |
| Single nucleus multiomics temporal profiling of islet immune cells in male and female NOD mice during UPR-deficiency-induced senescence | University of Wisconsin-Madison (Board of Regents University of Wisconsin System) | Feyza Engin | Cures | 01-February-2025 to 31-January-2028 | $750,000.00 |
| ICAM-1 Knock Out Pluripotent Stem Cells for Hypoimmune Type 1 Diabetes Therapy | University of Wisconsin-Madison (Board of Regents University of Wisconsin System) | Matthew Brown | Cures | 01-April-2025 to 31-March-2027 | $699,998.53 |
| Optimizing islet cell graft performance with targeted alpha and beta cell composition and distribution | Mayo Clinic | Quinn Peterson | Cures | 01-April-2025 to 31-March-2027 | $699,138.64 |
| Designing a safe and effective strategy for T1D cell replacement therapy | The Regents of the University of California, San Francisco | Nur Shabrina Amirruddin | Cures | 01-March-2025 to 29-February-2028 | $264,895.00 |
| Prediction of Cancer Immunotherapy Precipitated Autoimmune Diabetes | The Regents of the University of California, San Francisco | Zoe Quandt | Cures | 01-March-2025 to 28-February-2030 | $1,000,000.00 |
| Single-arm intervention trial of TWIIST™ AID DEKA Loop insulin pump in pregnant women with pre-existing type 1 diabetes | Stanford University | Tugce Akcan | Improving Lives | 01-March-2025 to 28-February-2027 | $180,600.00 |
| Engineered Nanobodies to Visualize and Direct Antigen-Specific Tolerance in T1D | Boston Children's Hospital | Novalia Pishesha | Cures | 01-March-2025 to 28-February-2030 | $999,999.00 |